

Decision

Decision Point: GF/B46/EDP21: Decision on the Secretariat's Recommendation on Funding from the 2020-2022 Allocation

The Board:

1. Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B46/ER21 ("Table 1");
2. Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;
3. Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and
4. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.

This decision does not have material budgetary implications for operating expenses.

Decision Point: GF/B46/EDP22: Decision on the Secretariat's Recommendation on Funding Unfunded Quality Demand from the 2017-2019 Allocation Period

The Board:

1. Approves the revised budget recommended for the grants listed in Table 2 of GF/B46/ER22 ("Table 2");
2. Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, and (b) is subject to the availability of funding; and
3. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.

This decision does not have material budgetary implications for operating expenses.

Decision Point: GF/B46/EDP23: Decision on the Secretariat's Recommendation on Grant Extensions

The Board:

1. Approves the extension budget and revised implementation period recommended for each grant listed in Table 3 of GF/B46/ER23 ("Table 3"); and
2. Affirms that any additional funding provided to fund the extension budget (a) shall increase the upper-ceiling amount that may be available for the relevant implementation period for each grant listed in Table

3, and (b) is subject to the availability of funding.

This decision does not have material budgetary implications for operating expenses.

Table 1: Secretariat's Recommendation on Funding from the 2020-2022 Allocation

Please note that each country name is [linked](#) to the extranet site where supporting documents are available for review.

N	Applicant	Disease Component	Grant Name ⁴	Grant End Date	Currency	Total Program Budget ⁵	Catalytic Funds in Grant	Domestic Commitment ⁶	Unfunded Quality Demand
1	Guatemala	TB	GTM-T-MSPAS	30/06/2025	US\$	4,387,112	-	TB: 11,831,776	1,877,316
2	Malaysia	HIV	MYS-H-MAC	30/06/2025	US\$	3,964,273	-	Commitment letter has yet to be received by the Global Fund	-
4	Multicountry Africa ECSCA-HC	TB	QPA-T-ECSA	30/06/2025	US\$	4,000,000	-	Multicountry grants are not subject to co-financing requirements.	-
3	Multicountry HIV SEA AFAO	HIV	QSA-H-AFAO	30/06/2025	US\$	12,500,000	-	Multicountry grants are not subject to co-financing requirements.	3,649,048
5	South Africa	HIV/TB	ZAF-C-AFSA	31/03/2025	US\$	109,588,291	-	HIV: 6,299,775,607 TB: 465,144,510	337,453,896
6			ZAF-C-BZ	31/03/2025	US\$	95,932,030	-	HIV: 6,299,775,607 TB: 465,144,511	
7			ZAF-C-NACOSA	31/03/2025	US\$	81,547,973	-	HIV: 6,299,775,607 TB: 465,144,512	
8			ZAF-C-NDOH	31/03/2025	US\$	259,698,331	10,000,000	HIV: 6,299,775,607 TB: 465,144,513	

⁴ The Grant names are subject to change based on the ISO code.

⁵ The Program budget for the Grant may be higher than the Program budget being recommended to the Board for approval where Covid-19 Response Mechanism funding has been integrated into the Grant.

⁶ Domestic commitments pertain to the disease programs and exclude other specific commitments for RSSH, unless otherwise specified. Commitments for disease specific programs and RSSH are subject to local currency value fluctuation against US dollar and Euro currencies. Please note that the domestic commitments included in this report are recorded as of the date of the GAC meeting and may be updated during implementation for countries that have been granted policy flexibilities.

Table 2: Secretariat's Recommendation on Additional Funding to Finance UQD from the 2017-2019 Allocation Period

Please note that each country name is [linked](#) to the extranet site where supporting documents are available for review.

N	Applicant	Disease Component	Grant Name	Additional Funding Source	Currency	Previously Approved Program Budget	Recommended Additional Funding	Revised Program Budget
1	Albania	HIV/TB	ALB-C-MOH	Portfolio Optimization	US\$	1,633,092	1,547,119	3,180,211

Table 3: Secretariat's Recommendation on Grant Extensions

N	Applicant	Disease Component	Grant Name	Currency	Budget for Proposed Extension Period	Additional Funding Required	Previous Extensions Granted (Cumulative in Months)	Proposed Extension Duration (Months)	Proposed End Date
1	Albania	HIV/TB	ALB-C-MOH	US\$	1,288,150	1,288,150 ⁷	-	24	31/12/2024

⁷ This amount is a portion of the total portfolio optimization award for Albania. Of the total (US\$1,547,119) requested, US\$258,969 will finance the scaling up of interventions during the ongoing implementation period and US\$1,288,150 is budgeted to finance the proposed 24-month extension.